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In view of the eminently important role of interleukin-2 (IL2) in T-cell responses, and in 
view of reports about immune stimulatory effects of PGEr, we reinvestigated the question 
whether PGEr inhibits IL-2 production. It was found that PGEz does not inhibit IL-2 production 
in murine spleen cell cultures after optimal stimulation (5 &ml concanavalin A) but does 
inhibit at suboptimal stimulation conditions. The failure of PGEr to inhibit IL-2 production at 
optimal concanavalin A concentration was demonstrated by two independent IL2 assays 
namely by the co-stimulator assay and by the proliferation of &Z-dependent T-cell clone W- 
2. Our observations indicated that the inhibitory effect of PGEr depends on the strength of the 
stimulating signal. IL2 production in cultures with 5 &ml concanavalin A was also not 
suppressed by PGE, , by prostaglandin Dz, thromboxane Br (T X B,), and prostaglandin Fr. 
0 1985 Academic Press. Inc. 
INTRODUCTION 
Prostaglandins of the E series and the lymphokine interleukin 2 (IL-2)’ play 
altogether an eminently important role as intercellular mediators in the regulation 
of T lymphocyte responses. Prostaglandins are produced by macrophages in the 
course of immunogenical reactions (reviewed in (1, 2)) and are also produced by 
various types of tumor cells (reviewed in (3)). Patients with Hodgkin’s disease have 
been found to contain prostaglandin-producing suppressor cells which are believed 
to be responsible for the depressed cellular immunity in these patients (4). It has 
also been reported that prostaglandins inhibit the rejection of tumors (3, 5); and 
prostaglandin of the E series, PGEl and PGE2, have been shown to inhibit the 
activation of cytotoxic T lymphocytes (CTL) (6, 7). Prostaglandins have been shown 
to inhibit the proliferative response of lymphoid cells including interleukin-Z 
dependent cytolytic T-cell lines (8- 12, reviewed in ( 1, 13)); and indomethacin and 
other inhibitors of prostaglandin synthesis have been shown to enhance the induction 
of cytotoxic responses against allogeneic cells (10). Recently, prostaglandins of the 
E type have also been reported to inhibit the production of IL-2 in human 
lymphocyte preparations (12, 14, 15). IL-2 of course, is of central importance for 
T-cell proliferation and for the generation of CTL responses as reviewed in (16). 
’ Abbreviations: CSCS, concanavalin A-activated spleen cell supematant; CTL, cytotoxic T Lymphocyte; 
IL-2, interleukin-2; PCS, prostaglandin; PGE2, prostaglandin El; PGIr , prostacyclin; TCF2, T cell 
cytotoxicity inducing factor 2; T X Br, thromboxane B2. 
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Recent reports about PGEz induced suppressor factors (17, 18) suggested, however, 
the possibility that such inhibitory factors might have interfered with the IL-2 assays 
and might have been responsible for the apparent reduction of the IL-2 titers by 
PGE2 in the reported experiments (12, 14, 15). Moreover, in spite of the numerous 
reports on the suppressive effects of prostaglandins, there are also reports that 
prostaglandins may augment T-cell reactivity under certain experimental situations. 
Anti-PGE antibodies have been reported to inhibit the in vivo development of 
several types of T-cell-mediated immune reactions (19). A PGE2 derivative (diM- 
PGE*) was found to increase T-cell-mediated immune repsonses in B16 melanoma- 
bearing C57BL/6 mice and delayed the development of the tumor whereas indo- 
methacin was found to enhance tumor development (20). And finally, PGEz. has 
also been implicated as possible mediator of the biological activity of thymic factor 
(21). In view of these stimulatory effects of PGEz, and in view of the central role of 
IL-2 in T-cell responses, we reinvestigated the question of whether PGE2 inhibits 
IL-2 production. Using two different IL-2 assays we found that PGE2 does not 
inhibit the production of IL-2 in murine spleen cell cultures with standard (optimal) 
concentrations of concanavalin A. 
MATERIALS AND METHODS 
Animals. The mice were obtained from Bomholtgard, Ry, Denmark. Most of the 
experiments were performed with 8- to lPweek-old male animals. 
The application of indomethacin and prostaglandins. Indomethacin is a nonsteroidal 
anti-inflamatory drug and a potent irreversible inhibitor of prostaglandin synthesis 
(22-24). A stock solution of indomethacin (Sigma) was prepared by dissolving 10 
mg/ml) in ethanol. The cell cultures contained usually 0.5 pg indomethacin per ml, 
i.e., 1:20,000 dilution of the stock solution in culture medium. The various types 
of prostaglandins were obtained from Sigma. Stock solutions (IO-* A4 in ethanol) 
were stored at -20°C. The prostaglandins were applied to cultures at concentrations 
of low6 M if not indicated otherwise. Control cultures with corresponding concen- 
trations of ethanol were also tested routinely. 
The preparation of Con A-activated spleen cell supernatant (CSCS). The CSCS 
preparations were obtained by culturing spleen cells (1 X lo7 cells/ml) with conca- 
navalin A (GIBCO) (5 pg/ml if not indicated otherwise) in culture medium with 
fetal calf serum (GIBCO) and 3 X 10e5 M 2-mercaptoethanol usually for 24 hr. 
(The CSCS preparations in Fig. 2 have been obtained after 48 hr incubation.) Some 
of the cultures contained also prostaglandins (10m6 M if not indicated otherwise) 
and/or indomethacin (usually 0.5 &ml). the supematants were isolated by centrif- 
ugation at 300g for 10 min and stored frozen. Some of the CSCS preparations were 
dialyzed 3 times against 10X the volume of culture medium in order to remove the 
prostaglandins. a-Methylmannoside at a final concentration of 1 mZl4 (0.194 mg/ 
ml) and HEPES (5 X lop3 M) were added to the supernatant in order to neutralize 
the contaminating concanavalin A. 
Assay for interleukin 2 with an IL-d-dependent T-cell line. Our interleukin 2 data 
are given as IL-2 activity units, based on the method described by Farrar et al. (25). 
The amount of IL2 in supematants was measured by their ability to support the 
growth of the T-cell clone W-2 as described in detail elsewhere (26). 
Costimulator assay (27). The determination of IL-2 by the costimulator assay 
was performed as described by Shaw et al. (27). Briefly, 1 X lo5 CBA thymocytes 
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were cultured with 0.6 pg concanavalin A and twofold dilutions of the CSCS 
preparation under test in 0.2 ml microcultures for 3 days. [3H]Thymidine (1 &i) 
was then added and the cultures were harvested on a Skatron cell harvester 4 
hr later. 
RESULTS AND DISCUSSION 
We observed that the IL2 production in spleen cell cultures with a standard 
concentration of 5 pg./ml of concanavalin A was not inhibited by PGE2 in 
concentrations up to 10m6 M as determined by the proliferation of the IL-2- 
dependent T-cell clone W-2 (Table 1) and by the costimulator assay (27) (Fig. 1). 
We found also that the presence of lop6 it4 PGE2 in Con A-stimulated spleen cell 
cultures did not alter the capacity of the resulting spleen cell blasts to absorb IL-2 
TABLE I 
The Effect of Prostaglandins on the Production of Interleukin 2 by Con A-Activated Spleen Cells” 
Group 
Indomethacin Prostaglandin 
added added Exp. I 
IL-2 units/ml 
Exp. II Exp. III 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
+ 
+ 
+ 
+ 
+ 
None 
None 
WE2 
6-Keto-PGF,, 
PfZO 
ED2 
T X B2 
10-6 M 
10-7 M 
lOa M 
lo+ M 
lo-‘M 
1O-6 M 
lo-’ M 
lO-6 M 
1O-6 M 
lO-6 M 
=I2 lO-6 M 
was added to CSCS prep. 
(Gr. 2) after Con A 
activation and dialysis 
None 
pGI2 lO-6 M 
was added to CSCS prep. 
(Gr. 2) after Con A 
activation and dialysis 
but was removed again 
by a second dialysis 
procedure 
43 
66 
57 
66 
61 
44 
69 
71 
100 148 
163 148 
146 n.t. 
135 
64 104 
111 146 
114 
124 
142 
176 
145 
140 
’ CBA spleen cells (3 X 108) were incubated in 30 ml culture medium with 0.15 mg concanavahn A 
plus the indicated materials. After 24 hr the supematants were collected by centrifugation and then 
subjected to dialysis for 24 hr to remove the prostaglandins. The supematants of groups 13 and 15 
received the prostaglandin only after this dialysis procedure; and the supematant in group 15 was then 
dialyzed a second time. These controls show that the IL-Z-dependent proliferation of W-2 cells is not 
inhibited by PG12. All supematants were finally mixed with cY-methylmannoside (1 mM) and tested for 
IL-2 activity. 
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FIG. 1. Effect of PGE2 on the activity of CSCS in the costimulator assay (27). Concanavalin A- 
stimulated thymocyte cultures received the indicated concentrations of a standard CSCS preparation 
without (0 - - - 0) or with (0 - 0) subsequent dialysis. A portion of the dialyzed CSCS preparation 
was mixed with PGEr ( lo4 M) and then tested in the costimulator assay (A - A). Another type of 
CSCS preparation was obtained by culturing the spleen cells with concanavalin A in the presence of 10m6 
M PGEl. This preparation was tested either without (A - - - A) or with (A - A) subsequent dialysis. 
A control preparation contained no CSCS but only the corresponding amounts of concanavalin A 
(X - X). A series of CSCS preparations which were obtained as described above but with the only 
difference that 0.5 &ml indomethacin was added to the Con A-stimulated spleen cell cultures gave the 
same pattern of results (data not shown). 
(data not shown). It was noted, however, that the IL-2 titers of CSCS preparations 
were (partly) inhibited when prostaglandin (PGI*) or its degradation product 6-keto- 
prostaglandin FI was added to the Con A-stimulated spleen cell cultures (Table 1). 
The CSCS preparations had been subjected routinely (except for group 13 in Table 
1 and the indicated groups in Fig. 1) to dialysis before the IL2 assay in order to 
remove the prostaglandins. The control group 13 in Table 1 showed that PGIl did 
not suppress the proliferation of the Il-Zdependent W-2 T-cell line directly. 
Prostaglandin E2 was found to suppress the proliferation of the W-2 cell line (Table 
2), but it was obviously completely removed by dialysis as indicated by the data of 
Tables 1 and 2. The inhibitory effect of PGE2 on the proliferation of an IL-2- 
dependent T-cell line has been described previously (11). 
However, PGEl failed to suppress the production of IL-2 only in spleen cell 
cultures with 5 &lml concanavalin A but not with 1 &ml concanavalin A (Fig. 
2). (The concentration of 5 &ml was in earlier experiments found to be the 
optimal concentration for the stimulation of IL-2 production and therefore routinely 
used as a standard concentration.) 
Taken together, our experiments revealed that PGE2 did not inhibit the IL-2 
production in murine spleen cell cultures after optimal stimulation (5 &ml 
concanavalin A) as determined by two independent IL2 assays, whereas IL-2 
production in cultures with 1 pg/ml concanavalin A was markedly reduced. This 
indicated that the inhibitory effect of PGEz depends on the strength of the activating 
signal. Our experiments are not incompatible with the series of reports that PGEz 
inhibits IL-2 production in cultures of mitogen activated human lymphocytes (12, 
14, 15). Possibly, these studies have been dealing with suboptimal stimulation 
conditions. The possibility that the IL-2 assays might have been sensitive against a 
PGEz-induced suppressor factor might also explain the PGE2-mediated inhibition 
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TABLE 2 
Effect of PGE, on the Proliferation of the W-2 CelI Line (on the Apparent IL-2 Titers)’ 
Factor and materials added Apparent IL2 units/ml 
Exp. I 
Gr. 1 CSCS cont. 130 
2 CSCS 1:3 diluted 26 
3 cscs 1:9 diluted 8.5 
4 CSCS cont. + PGEr ( 10e6 M) 51 
5 CSCS 1:3 + PGE2 (IO+ M) 13 
6 CSCS I:9 + PGEZ (IO-‘j M) 3.4 
Exp. II 
Gr. 7 CSCS 
8 CSCS + PGE2 (lo+ M) 
9 CSCS + PGEz ( 10m6 M) dialysed 
160 
110 
154 
Exp. III 
Gr. 10 El-4 sup. 100 
11 EL-4 sup. + PGE2 (lo-’ M) 28 
0 The IL-2 titer of two different CSCS preparations and an IL2 containing EL4 supematant alone or 
in mixture with PGEz was assayed as described under Materials and Methods. In group 9, the mixture of 
CSCS plus PGE2 had been dialyzed before the assay. Apparently, the prostaglandin was almost completely 
removed. 
in the previous reports (12, 14, 15) and in our experiment of Fig. 2. Several 
laboratories have reported that PGE2 activates inhibitory T cells (2%30), which 
produce suppressor factors ( 17, 18). 
Our experiments howed also that PGE2 inhibits the IL-2-dependent cell prolif- 
eration. This effect of PGE2 is probably mediated by increased cyclic AMP levels in 
. . .-. cscs 5pg CcmA 
yJ 
0 
x 
g 20 
L' 
30 I 
10 
. 
o- -o cscs 5,ug ConA + PGE, 
.-. cSCS 1 pg ConA 
o-0 cSCS I JIM ConA + PGE, 
o-,- 4 
-- ~~-----o-----o-- ---o --_ ---_ -0 ---0 
o+ 
1:4 
I I r I /I I 
1:8 1:16 1:22 I:64 1512 
dilution of CSCS preparation 
FIG. 2. PGE;? inhibits the stimulation of IL-2 production by low concentrations of concanavalin A. 
CSCS was either prepared with 5 &ml concanavalin A and without PGE2 (standard conditions, 
n - n ), or with 5 &ml Con A and with 1 Oe6 M) PGEa (0 - - - q ), with 1 &ml Con A and without 
PGEr (0 - l ), or with 1 &ml Con A and with 10e6 M PGEa (0 - - - 0). All CSCS preparations 
were dialyzed and subsequently tested for IL2 activity in the costimulator assay (27). PGE, was found 
to reduce the apparent IL-2 titer in Con A-activated spleen cell cultures with 1 &ml Con A but not 
with 5 &ml Con A. 
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the target cells (1). The possibility that PGE2 reduces the expression of IL-2 receptors 
seems less likely; at least in Con A-activated spleen cell cultures PGE2 did not alter 
the capacity to absorb IL-2 (unpublished observation). 
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